Tumor lysis syndrome diagnostic criteria: Difference between revisions
Jump to navigation
Jump to search
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The diagnosis of tumor lysis syndrome is based on the Cairo–Bishop criteria, which include [[uric acid]], [[potassium]], phosphorous, and [[calcium]].<ref name="pmid15384972">{{cite journal| author=Cairo MS, Bishop M| title=Tumour lysis syndrome: new therapeutic strategies and classification. | journal=Br J Haematol | year= 2004 | volume= 127 | issue= 1 | pages= 3-11 | pmid=15384972 | doi=10.1111/j.1365-2141.2004.05094.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15384972}}</ref> | The diagnosis of tumor lysis syndrome is based on the Cairo–Bishop criteria, which include [[uric acid]], [[potassium]], phosphorous, and [[calcium]].<ref name="pmid15384972">{{cite journal| author=Cairo MS, Bishop M| title=Tumour lysis syndrome: new therapeutic strategies and classification. | journal=Br J Haematol | year= 2004 | volume= 127 | issue= 1 | pages= 3-11 | pmid=15384972 | doi=10.1111/j.1365-2141.2004.05094.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15384972}}</ref> | ||
==Diagnostic Criteria== | ==Diagnostic Criteria== | ||
The diagnosis of tumor lysis syndrome is based on the Cairo–Bishop criteria:<ref name="pmid15384972">{{cite journal| author=Cairo MS, Bishop M| title=Tumour lysis syndrome: new therapeutic strategies and classification. | journal=Br J Haematol | year= 2004 | volume= 127 | issue= 1 | pages= 3-11 | pmid=15384972 | doi=10.1111/j.1365-2141.2004.05094.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15384972}}</ref> | The diagnosis of tumor lysis syndrome is based on the Cairo–Bishop criteria:<ref name="pmid15384972">{{cite journal| author=Cairo MS, Bishop M| title=Tumour lysis syndrome: new therapeutic strategies and classification. | journal=Br J Haematol | year= 2004 | volume= 127 | issue= 1 | pages= 3-11 | pmid=15384972 | doi=10.1111/j.1365-2141.2004.05094.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15384972}}</ref> | ||
Revision as of 19:20, 23 September 2015
|
Tumor lysis syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tumor lysis syndrome diagnostic criteria On the Web |
|
American Roentgen Ray Society Images of Tumor lysis syndrome diagnostic criteria |
|
Risk calculators and risk factors for Tumor lysis syndrome diagnostic criteria |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
The diagnosis of tumor lysis syndrome is based on the Cairo–Bishop criteria, which include uric acid, potassium, phosphorous, and calcium.[1]
Diagnostic Criteria
The diagnosis of tumor lysis syndrome is based on the Cairo–Bishop criteria:[1]
- Laboratory tumor lysis syndrome: abnormality in two or more of the following within 3 days before or 7 days after starting chemotherapy:
- Hyperuricemia ≥ 476 μmol/l
- Hyperphosphatemia ≥ 2·1 mmol/l (children), x ≥1·45 mmol/l (adults)
- Hyperkalemia ≥ 6·0 mmol/l
- Hypocalcemia ≤ 1·75 mmol/l
- Clinical tumor lysis syndrome: laboratory tumor lysis syndrome plus one or more of the following:
- Increase serum creatinine (1.5 times upper normal limit)
- Cardiac arrhythmia or sudden death
- Seizure
References
- ↑ 1.0 1.1 Cairo MS, Bishop M (2004). "Tumour lysis syndrome: new therapeutic strategies and classification". Br J Haematol. 127 (1): 3–11. doi:10.1111/j.1365-2141.2004.05094.x. PMID 15384972.